Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Lexaria Bioscience Corp.

    NASDAQ: LEXX · Real-Time Price · USD
    0.80
    0.00 (0.13%)
    At close: Aug 15, 2025, 3:59 PM
    0.82
    2.44%
    After-hours: Aug 15, 2025, 04:00 PM EDT
    0.13%
    Bid 0.77
    Market Cap 15.65M
    Revenue (ttm) 615.92K
    Net Income (ttm) -11.39M
    EPS (ttm) -0.68
    PE Ratio (ttm) -1.18
    Forward PE -1.76
    Analyst Buy
    Ask 0.86
    Volume 98,498
    Avg. Volume (20D) 146,717
    Open 0.82
    Previous Close 0.80
    Day's Range 0.80 - 0.85
    52-Week Range 0.78 - 4.38
    Beta 0.79

    About LEXX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol LEXX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for LEXX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Lexaria Bioscience Corp. is scheduled to release its earnings on Nov 25, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 months ago
    -20.12%
    Lexaria Bioscience shares are trading lower. The c... Unlock content with Pro Subscription
    7 months ago
    -6.31%
    Lexaria Bioscience shares are trading lower. The company announced partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3.
    news image

    1 day ago · thenewswire.com

    Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

    Kelowna, British Columbia –   TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased...

    news image

    1 week ago · accessnewswire.com

    GLP-1 "Arms Race" Broadens to Include Dozens of Companies

    Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria...

    news image

    2 weeks ago · accessnewswire.com

    Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

    DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus® DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus® DehydraTECH-GLP-1...

    news image

    2 weeks ago · thenewswire.com

    Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

    DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus  DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus

    news image

    3 weeks ago · thenewswire.com

    Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

    The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects  DehydraTECH reduces side effects and could support patient ret...

    news image

    1 month ago · accessnewswire.com

    Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

    New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...

    news image

    2 months ago · accessnewswire.com

    Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

    Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R))  Lexaria has now demonstrated, in distinct human clinical studies,...

    news image

    2 months ago · accessnewswire.com

    Lexaria Attending BIO International Convention

    Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global inn...

    Add to Watchlist